Comorbidities Remission After Roux-en-Y Gastric Bypass for Morbid Obesity is Sustained in a Long-Term Follow-up and Correlates with Weight Regain
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Obesity-related comorbidities are treated by Roux-en-Y gastric bypass (RYGB) due to weight loss and intestinal hormone changes. Few studies report the evolution of these comorbidities in a long-term follow-up, especially if weight regain is present. This study aims to analyze: (1) the resolution of obesity-related comorbidities after RYGB in a long-term follow-up and (2) its relationship to weight regain.
A retrospective study was conducted on 140 patients submitted to RYGB for morbid obesity for at least 5 years (mean follow-up 90 months). Mean body mass index (BMI) before operation was 52 kg/m2, at nadir weight 29 kg/m2, and at last follow-up 33 kg/m2. The comorbidities diabetes, cardiovascular disease, arterial hypertension, dyslipidemia, sleep apnea, arthropathy, and infertility were classified as resolved, improved, unchanged, and worsened at nadir weight that happened between the first and second year and after five or more years of surgery. For each comorbidity, we compared the changes in the distribution of patients in the categories and the correlation of it with weight loss at the nadir and final weight.
BMI was significantly different in the three periods. Comorbidities resolution was sustained in a long-term follow-up for diabetes, hypertension, cardiovascular disease, and infertility. Comorbidities status was directly related to the weight loss for all comorbidities except infertility.
Our results show that comorbidities remission after RYGB is sustained in a long-term follow-up. Weight regain is linked to worse results for all comorbidities except infertility.
- Magro DO, Geloneze B, Delfini R, et al. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg. 2008;18:648–51. CrossRef
- Christou NV, Look D, MacLean LD. Weight gain after short and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg. 2006;244:734–40. CrossRef
- Sugerman HJ, Wolfe LG, Sica DA, et al. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg. 2003;237(6):751–8.
- White S, Brooks E, Jurikova L, et al. Long-term outcomes after gastric bypass. Obes Surg. 2005;15:155–63. CrossRef
- National Institutes of Health Consensus Development Conference Statement. Gastrointestinal surgery for severe obesity. Am J Clin Nutr. 1992;55:615S–9S.
- Shape Up America! Organization and the American Obesity Association. Guidance for treatment of adult obesity. Bethesda: Maryland;1996.
- Oria HE, Moorehead MK. Updated Bariatric Analysis and Reporting Outcome System (BAROS). Surg Obes Relat Dis. 2009;5:60–6. CrossRef
- Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549–55. CrossRef
- Dietel M. Overweight and obesity worldwide now estimated to involve 1.7 billion people. Obes Surg. 2003;13:329–30. CrossRef
- Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–29. CrossRef
- Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA. 2003;289:187–93. CrossRef
- Choban PS, Jackson B, Poplawski S, et al. Bariatric surgery for morbid obesity: why, who, when, how, where, and then what? Cleveland Clin J Med. 2002;69:897–903. CrossRef
- Buchwald H, Estok R, Fahrbach K, et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery. 2007;142:621–35. CrossRef
- Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish subjects. N Engl J Med. 2007;357:741–52. CrossRef
- Christou N, Sampalis JS, Liberman M, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg. 2004;240:416–24. CrossRef
- Valezi AC, Mali Jr J, Menezes MA, et al. Weight loss outcome after silastic ring Roux-en-Y gastric bypass: 8 years of follow-up. Obes Surg. 2010;20:1491–95. CrossRef
- Buchwald H, Avidor Y, Braunwald E, et al. Bariatric Surgery. A systematic review and meta-analysis. JAMA. 2004;292(14):1724–38. CrossRef
- Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93. CrossRef
- Dhabuwala A, Cannan RJ, Stubbs RS. Improvement in co-morbidities following weight loss from gastric bypass surgery. Obes Surg. 2000;10:428–35. CrossRef
- Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004;89(6):2608–15. CrossRef
- le Roux CW, Aylwin SJB, Batterhan RL, et al. Gut hormones profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243(1):108–14. CrossRef
- Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240(2):236–42. CrossRef
- Comorbidities Remission After Roux-en-Y Gastric Bypass for Morbid Obesity is Sustained in a Long-Term Follow-up and Correlates with Weight Regain
Volume 22, Issue 10 , pp 1580-1585
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Morbid obesity
- Obesity surgery
- Gastric bypass
- Long-term follow-up
- Weight loss
- Industry Sectors
- Author Affiliations
- 1. Department of Surgery, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil
- 2. Department of Surgery, Mandaqui Hospital, São Paulo, Brazil
- 3. Rua Dona Adma Jafet 50 cj 125, São Paulo, SP, Brazil, 01308-050